We evaluated the effect of interleukin-12 (IL-12) gene therapy using an Ewing's sarcoma animal model in T-cell-deficient nude mice. Subcutaneous injection of TC71 cells resulted in tumor development by day 5. Mice were treated with a single intratumor injection of adenovirus b-galactosidase (Ad.b-gal) or adenovirus murine IL-12 (Ad.mIL-12) (2 Â 10 9 PFU) and killed 1-7 days later. 
Introduction
Ewing' sarcoma, a primitive neural ectodermal tumor, is the second most common primary malignant bone tumor in children and young adults. Despite many attempts to improve the 5-year disease-free survival using various chemotherapeutic regimens, the survival rates have been unchanged for the past 15 years hovering at about 40-60% depending on tumor location and metastases at presentation. 1, 2 The prognosis for patients with relapses is dismal, as salvage chemotherapeutic regimens are rarely effective. [3] [4] [5] New therapeutic strategies are therefore needed if the mortality rates are to be improved in this disease.
Interleukin-12 (IL-12) is a heterodimer composed of two subunits (p35 and p40), linked by a disulfide bond. 6, 7 This cytokine is a key participant in a variety of immune activities including the stimulation of T cells and natural killer (NK) cells and the regulation of cell adhesion molecules. [6] [7] [8] In addition to its immune-stimulating capacity, IL-12 has also been shown to be antiangiogenic. 9 Significant antitumor activity has been demonstrated in several animal models, [10] [11] [12] and clinical trials have indicated the potential antitumor activity of this cytokine. [13] [14] [15] We have previously demonstrated that IL-12 gene therapy induces the regression of another bone tumor, osteosarcoma. 16, 17 In this report, we demonstrate that the intratumoral injection of an adenoviral vector carrying the murine IL-12 gene (adenoviral mIL-12 (Ad.mIL-12)) inhibited the growth of both local and distant Ewing's sarcoma tumors in mice, prolonging animal survival. In addition, we demonstrate that IL-12 upregulated the expression of Fas and Fas ligand (FasL). Fas is a cell surface molecule capable of inducing ligand-mediated apoptosis. 18 The ability of IL-12 to increase Fas/FasL expression may contribute to its antitumor activity, as Fas-mediated apoptosis and the overexpression of Fas have been linked to tumor regression. 19, 20 Our data indicate that IL-12 may be a therapeutic option for patients with Ewing's sarcoma.
Materials and methods

Reagents
Eagle's minimal essential medium (EMEM), Hanks' balanced salt solution (HBSS) without calcium or magnesium, nonessential amino acids, sodium pyruvate, MEM vitamins, L-glutamine and 2.5% trypsin were purchased from Whitaker Bioproducts (Walkersville, MD). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, GA). All reagents were free of endotoxin as determined using the Limulus amebocyte lysate assay (sensitivity limit, 0.025 ng/ml) purchased from Sigma (St Louis, MO).
Cell lines
The 293 human embryonic kidney cells transformed with fragments of adenovirus type 5 DNA, purchased from American Type Culture Collection (Manassas, VA), were maintained in Dulbecco's modified Eagle's medium (GIBCO, Grand Island, NY) supplemented with Lglutamine and 10% heat-inactivated FBS (561C for 30 min). TC71 human Ewing's sarcoma cells, a gift from Dr P Pepe (University of Southern California, Los Angeles, CA) were maintained in EMEM supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 1 Â nonessential amino acids, 2 Â MEM vitamins and 10% heat-inactivated FBS. The monolayer culture of cells was maintained in a 371C humidified 5% CO 2 incubator. The cells were tested periodically for mycoplasma contamination by reverse transcriptase-polymerase chain reaction (RT-PCR) (primer purchased from Sigma Genosys, Woodland, TX) and were verified to be free of pathogenic murine viruses (NCI-Frederick Cancer Research & Development Center, Frederick, MD).
Mice Four-to five-week-old specific pathogen-free athymic (T-cell deficient) nude mice were purchased from Charles River Breeding Laboratories (Kingston, MA). The mice were maintained and fed in a specific pathogen-free animal facility approved by the American Association of Laboratory Animal Care in accordance with current regulations and standards of the United States Department of Agriculture, The Department of Health and Human Services and the National Institutes of Health. Mice were housed five to a cage and kept in a laminar flow cabinet under specific pathogen-free conditions, with a 12-h dark cycle, at least 1 week before initiation of the investigations.
Vectors
Ad.mIL-12, the bicistronic adenoviral vector carrying both the p35 and p40 subunits of murine cDNAs 10 , was a gift from Dr Steven K Clinton (Ohio State University, Columbus, OH). Ad.mIL-12 was prepared by superinfecting 293 cells, purifying twice by cesium chloridegradient ultracentrifugation and then dialyzing the final product. An adenoviral vector containing the b-galactosidase gene (Ad.b-gal) served as the vector control. The titers of virus were measured by plaque-forming units (PFU) assay and then stored at À801C.
TC71 cells in exponential growth phase were harvested, and then incubated with medium alone, medium containing Ad.b-gal (100 PFU/cell) or medium containing Ad.mIL-12 (10, 50, 100 and 300 PFU/cell) for 48 h.
The total RNA was extracted using TRIzol reagent (Life Technologies Inc., Gaithersburg, MD). The expression of p35 and p40 IL-12 subunits was confirmed by RT-PCR analysis.
Flow cytometric analysis
Fas expression was assayed by flow cytometry. TC71 cells (10 6 ) were treated with Ad.b-gal (250 PFU/cell) or Ad.mIL-12 (250 and 500 PFU/cell) for 48 h. Cells were then harvested by trypsinization, washed with phosphatebuffered saline (PBS) and fluorescence-activated cell sorter (FACS) buffer (2% FBS, 10% NaAzide in D-PBS), and incubated with 1 mg of R-PE-conjugated mouse anti-human Fas antibody (clone DX2, Pharmingen, San Diego, CA) or 1 mg of isotype-matched PE-conjugated control mouse anti-human IgG antibody (Sigma Chemical Co., St Louis, MO) on ice in the dark for 40 min. After being washed twice with FACS buffer, samples were analyzed by a FACScan (Becton Dickenson, Mountain View, CA).
In vivo transfection TC71 cells in exponential growth phase were harvested by trypsinization. The cells (2 Â 10 6 ) in 0.1 ml HBSS (41C) were injected subcutaneously (s.c.) into the flank of nude mice (day 0). When tumors measured 5-6 mm in diameter (day 12), mice were anesthetized and given one intratumoral injection of Ad.b-gal (2 Â 10 9 PFU in 50 ml PBS) or Ad.mIL-12 (2 Â 10 9 PFU in 50 ml PBS). Control mice were given intratumor injection with 50 ml PBS. Mice were killed at 1, 2, 3, 4 and 7 days after treatment. The tumors were excised and total RNA was extracted by homogenization in TRIzol reagent. Expression of both p35 and p40 IL-12 mRNA was analyzed by RT-PCR.
Intratumor gene therapy Mice were injected s.c. with TC71 cells (2 Â 10 6 ) in 0.1 ml cold HBSS. When tumors measured 2-3 mm in diameter (day 5 or 6), mice were randomly divided into three groups and received intratumoral injections of Ad.b-gal or Ad.mIL-12 (2 Â 10 9 PFU), or PBS twice weekly for five injections. The therapeutic effect was assessed by changes in tumor volume. Two perpendicular diameters of each tumor were measured with calipers twice weekly. The volume of the tumor was calculated using the formula (a Â b 2 /2), where a is the longer diameter and b is the shorter diameter. Mice were killed when tumors reached 2 cm in diameter. This served as the survival end point.
To determine the effect of intratumoral therapy on distant tumors, TC71 cells (2 Â 10 6 ) were injected s.c. into the right flank. When the tumor measured 2-3 mm in diameter (day 5 or 6), mice were randomly divided into three groups and given intratumoral injections of either Ad.b-gal or Ad.mIL-12, or PBS twice weekly for five injections. Mice were then injected s.c. with TC71 cells into the left flank when the second dose of Ad.b-gal or Ad.mIL-12 therapy was given on day 8 or 9. Three additional doses were injected into the right tumor. The left tumors received no therapy. The growth of tumors on both sides was monitored by volume as before.
The perpendicular diameters of the tumors were measured twice weekly.
Tumors were excised when they reached 2 cm in diameter. Mice whose tumors were excised were then monitored for tumor relapse and the development of metastases for 22-69 days following tumor excision. By which time, mice were killed for investigation of lung, lymph nodes and bone metastases. . Classic II 18S primer/competimers (18S internal standards, 324 bp, Ambion, Austin, TX) was used for an internal control. The total volume was 50 ml. The primer was designed to produce a 648-bp fragment for mIL-12 p35 and 1010 bp for mIL-12 p40. The PCR products were isolated by electrophoresis on 2% agarose gel stained with ethidium bromide and visualized under ultraviolet light. The results were quantified using the Quantity one machine (Bio-Rad, Hercules, CA).
RT-PCR
IL-12 and interferon-g enzyme-linked immunosorbent assay
To determine in vivo IL-12 and interferon-g (IFNg) protein production, intratumor Ad.mIL-12 and Ad.b-gal (1 Â 10 9 PFU) were given to TC71 tumor-bearing mice twice 3 days apart. Two days latter, blood was collected from the renal artery under anesthesia. Isolated serum was aliquoted and stored at À801C for use. Tumor tissues were removed and homogenized with lysis buffer (20 mM Tris (pH 8), 137 mM NaCl, 10% (w/v) glycerol, 1% Triton, 2 mM ethylenediaminetetraacetic acid (pH 8), 0.1 mM phenymethylsulfonyl fluoride, 1 mg/ml of aprotinin, 1 mg/ml of leupeptin and 1 mg/ml of pepstatin). These homogenates were vortexed, incubated on ice for 20 min and then spun. The supernatants were collected and stored at À801C. The IL-12 protein level in serum and in homogenate supernatants from tumor were quantified by enzyme-linked immunosorbent assay (ELISA) (Endogen Inc., Woburn, MA) according to the manufacturer's recommendation. The IFNg protein level in tumor was also quantified by ELISA (Endogen Inc.).
Immunohistochemical analysis
Both right (treated) and left (untreated) TC71 tumors were excised, washed with PBS and fixed in 10% formalin or snap frozen in liquid nitrogen. The sections were then subjected to analyses with hematoxylin and eosin staining.
To determine expression of IL-12, CD31 and NK cells, frozen sections (5 mm) were fixed with acetone, treated with 3% H 2 O 2 to inactivate endogenous peroxidase and then incubated in 5% normal horse serum (NHS) plus 1% normal goat serum (NGS) in PBS to block nonspecific sites. The sections were treated with rat anti-mouse monoclonal IL-12 antibody (1:30 dilution; Biosource International Inc., Camarillo, CA), rat anti-mouse CD31 (1:800 dilution; Pharmingen), or rat anti-mouse pan-NK cells antibody (1:500 diluted; Pharmingen) as a primary antibody and goat anti-rat horseradish peroxidase (HRP, 1:200 diluted; Jackson Immuno Research Laboratory Inc., West Grove, PA) as the secondary antibody of IL-12, CD31, and goat anti-rat IgM (1:100 diluted, Pierce, Rockford, IL) as the secondary antibody of NK cells before incubation with chromogen diaminobenzidine (DAB, Research Genetics, Hunttsville, AL). Signals were monitored by light microscopy followed by counterstaining with Gill's hematoxylin.
We assessed expression of Fas, FasL and vascular endothelial growth factor (VEGF) in paraffin-embedded sections. The sections were deparaffinized, heated with citrate buffer (pH 6) in a microwave oven (on 750 W) for 5 min and then cooled for antigen retrieval. The sections were treated with 3% H 2 O 2 to block endogenous peroxidase and incubated with NHS/NGS to block nonspecific sites. Fas and FasL expression were detected using mouse anti-human Fas (CD95, APO-1) antibody (1:100 diluted; Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-human FasL antibody (1:100 diluted; Pharmingen, San Diego, CA) as a primary antibody. Goat anti-mouse IgG (1:500 dilution; Pharmingen) and goat anti-rabbit IgG (1:500 diluted; Jackson Immune Research Laboratory) served as the secondary antibody. Expression of VEGF was detected by staining with rabbit anti-rat antibody (1:500 dilution; Santa Cruz Biotechnology) as the primary antibody and goat anti-rabbit HRP (1:500 dilution; Jackson Immune Research Laboratory) as the secondary antibody. After being rinsed with PBS, the sections were incubated with DAB. Signals were monitored by light microscopy followed by counterstaining with Gill's hematoxylin. Negative control samples were treated with NHS/NGS only before staining with the secondary antibody as described above.
TdT-mediated dNTP nick end labeling analysis Frozen tissue sections fixed with 4% formaldehyde were treated with 3% H 2 O 2 to block endogenase peroxidase and then incubated with proteinase K (20 mg/ml) for 15 min. After being rinsed with terminal deoxynucleotidyl transferase (TdT) buffer (30 mM Trizma pH 7.2, 140 mM sodium cacodylate and 1 mM cobalt chloride in doubledistilled (dd) water), the sections were incubated with terminal transferase (1:400 diluted in TdT buffer; Boehringer Mannhaim Corp., Indianapolis, IN) and biotin-16-dUTP (1:200 diluted in TdT buffer; Roche, Indianapolis, IN) in a humidified dark chamber at 371C for 45 min. The enzymatic reaction was terminated by rinsing the sections with TB buffer (300 mM NaCl and 30 mM sodium citrate in dd water) twice, and then rinsing them with dd water. The sections were incubated with 2% BSA/NHS in dd water for 10 min, followed by treatment with peroxidase streptavidin (1:400 diluted in horse detection diluent) for 30 min in a 371C humidified chamber. The sections were then rinsed three times in PBS, treated with DAB for 5 min and then counterstained with Gill's hematoxylin.
Statistical analysis
Differences in tumor volume, tumor weight and tumor vessel numbers were evaluated using the two-tailed Student's t-test. The mouse survival rate was evaluated using the Kaplan-Meier analysis. P-value o0.05 was considered statistically significant. We next determined whether Ad.mIL-12 could be used to deliver the mIL-12 gene to Ewing's sarcoma tumors in vivo. Tumor-bearing mice (day 12) were given a single intratumoral injection of Ad.mIL-12 or Ad.b-gal (2 Â 10 9 PFU). Mice were killed 1, 2, 3, 4 and 7 days later. The tumors were excised and total RNA extracted for RT-PCR analysis. As shown in Figure 2 , tumors injected with single dose Ad.mIL-12 demonstrated expression of both the p35 and p40 subunits of mIL-12 on day 1 (24 h), with peak expression occurring on day 2 (48 h). IL-12 expression persisted for up to 7 days. There was no IL-12 expression in the untreated tumors or those treated with intratumoral Ad.b-gal.
Results
IL
Ad.mIL-12 intratumor therapy inhibits the growth of Ewing's sarcoma
We next assessed the effect of intratumor injection of Ad.mIL-12 on tumor growth. Tumor-bearing mice were treated with Ad.mIL-12 or Ad.b-gal (2 Â 10 9 PFU), or PBS twice weekly for 2.5 weeks (five injections) starting 5 days after tumor cell inoculation. As shown in Figure 3a and c tumor growth was significantly inhibited by intratumor Ad.mIL-12. On day 32, the tumor weight and size were significantly reduced in Ad.mIL-12-treated mice compared to mice treated with Ad.b-gal (Figure 3b Figure 4 ). Ad.mIL-12-treated mice did not relapse and had no evidence of metastatic disease in lung, lymph nodes or bone when examined on day 69 (data not shown).
IL-12 protein in tumor tissues and serum following intratumor Ad.mIL-12 therapy We next determined whether intratumor Ad.mIL-12 gene therapy resulted in significant levels of IL-12 protein in blood and tumor tissue. Tumor-bearing mice were given intratumor Ad.mIL-12 or Ad.b-gal twice 3 days apart, starting 12 days after tumor inoculation. Two days latter, serum and tumor were collected. As shown in Table 1 , the levels of IL-12 protein in the tumor from mice receiving Ad.mIL-12 were 10-fold higher compared to those from mice treated with Ad.b-gal. Serum IL-12 levels in mice treated with Ad.mIL-12 were also higher. By contrast, levels of IFN-g were similar in the Ad.mIL-12-treatedand Ad.b-gal-treated tumors. 
smaller in mice that received intratumor Ad.mIL-12 compared to mice that received intratumor Ad.b-gal (Pp0.02 and Pp0.034 respectively).
Effect of Ad.mIL-12 on tumor vessel density, tumor cell apoptosis and expression of Fas, FasL and VEGF Previous studies demonstrated that IL-12 upregulated Fas expression in osteosarcoma cells. 15 As shown in Figure 6 , Ad.mIL-12 increased Fas expression in TC71 cells in vitro.
The expression of Fas and FasL was increased in both the Ad.mIL-12-treated ( Figure 7 ) and untreated (Table 2) tumors. In addition, the expression of VEGF and CD31 was decreased in both the treated ( Figure 7 ) and untreated (Table 2) tumors with an increase into tumor cell apoptosis ( Figure 7 , Table 2 ). There was also an increase in macrophages but not NK cells in the IL-12-treated tumors (data not shown). No expression was demonstrated in the negative control samples.
Discussion
In this study, we used the subcutaneous inoculation of TC71 cells, which allowed easy monitoring of tumor growth and therapeutic response to intratumor Ad.mIL-12. We used murine rather than human IL-12, as mIL-12 has been shown to be active both in human and murine cells. 21 By contrast, human IL-12 does not cross species barriers and only stimulate human cells. We wanted to investigate the host response to therapy in addition to the effect of IL-12 on the tumor cells. We demonstrated that Ad.mIL-12 can be transfected into human Ewing's sarcoma cells in vitro and in vivo. A single or two doses of Ad.mIL-12 injected into the established tumor resulted in expression of IL-12 as well as the local and systemic production of IL-12 protein. Multiple intratumor injections of Ad.mIL-12 resulted in inhibition of both local and distant tumor growth and increased animal survival.
The systemic administration of IL-12 protein has been shown to inhibit tumor growth and prevent spontaneous metastases to lung and lymph nodes in several different animal tumor models. 12, [22] [23] [24] [25] In clinical trials, although tumor regression was documented the systemic administration of IL-12 protein resulted in undesirable effects. 26 These toxicities were linked to IFN-g. Both serum IFN-g levels and the toxic effects were diminished when a test dose of IL-12 was administered 2 weeks before initiation of therapy. 27 We hypothesized that direct injection of the IL-12 gene into tumor tissue would result in the local production of high concentrations of IL-12, specifically at the target site. We further hypothesized that this would result in lower serum IL-12 protein and IFN-g levels. Although both tumor and serum levels of IL-12 were higher in the mice treated with intratumor Ad.mIL-12, there was no difference in IFN-g levels. These data support our concept that intratumor IL-12 gene therapy may be less toxic. Interestingly, we were also able to demonstrate IL-12 protein in the untreated contralateral tumor from animals treated with Ad.mIL-12 gene therapy ( Table 2 ). This may be secondary to the circulating IL-12 in the serum. This circulating IL-12 may have contributed to the growth inhibition on the untreated contralateral tumor. We cannot rule out, however, an immunemediated mechanism at this time. IL-12 has been shown to stimulate T cells and NK-cell activity. We were, however, unable to demonstrate NK cell infiltration following intratumor IL-12 gene therapy in either the Abbreviations: Ad.b-gal, adenovirus b-galactosidase; Ad. mIL-12, adenovirus murine IL-12; IFN-g, interferon-g; IL-12, interleukin-12; mIFN-g, murine interferon-g; mIL-12, murine interleukin-12.
a TC71 Ewing's sarcoma-bearing mice were intratumorally injected with Ad.b-gal, Ad.mIL-12 (1 Â 10 9 pfu/50 ml PBS) or PBS twice given 3 days apart. Mice were killed 2 days later.
b Serum was isolated and levels of IL-12 or IFN-g quantified by ELISA.
c Protein was extracted from excised tumor tissue using lysis buffer (1 mg tumor tissue/10 ml buffer). Levels of IL-12 or IFN-g were then quantified by ELISA. Our previous studies demonstrated that IL-12 directly upregulated Fas expression on human osteosarcoma cells. This effect was independent of IFNg. 18 Fas is a 43-kDa type I membrane protein that is expressed on a variety of normal and neoplastic cells. FasL binds to cell surface Fas, which will in turn induce cell apoptosis. 28 Zhang Intratumor Ad.mIL-12 gene therapy for Ewing's sarcoma S-F Jia et al Figure 7 Effect of intratumoral Ad.mIL-12 on Fas, FasL, apoptosis, VEGF and CD31. TC71 tumors were excised 2 days after receiving two intratumor injections (3 days apart) of either Ad.mIL-12 or Ad.b-gal. Frozen sections were fixed with acetone and then stained with rat anti-mouse monoclonal IL-12 antibody or rat anti-mouse CD31. Paraffin-embedded tissue sections were deparaffinized, antigen retrieved and stained with mouse anti-human Fas antibody, mouse anti-human FasL antibody or anti-VEGF. TdT-mediated dNTP nick end labeling analysis was used to quantify tumor cell apoptosis. Negative control samples were treated as described in Materials and methods. Abbreviations: Ad.b-gal, adenovirus b-galactosidase; Ad.mIL-12, adenovirus murine IL-12;FasL, Fas ligand; IL-12, interleukin-12; VEGF, vascular endothelial growth factor. a Mice bearing TC71 tumors in the right flank were treated three times with Ad.mIL-12 or Ad.b-gal or PBS given on day 6, 9 and 13. TC71 cells were injected in the contralateral (left) flank on day 9 (when the second dose of therapy was given). The left tumor received no therapy. Tumors were excised on day 15 (2 days following the last dose therapy) and examined by immunohistochemistry. Staining was assessed from + (weak) to ++++ (very strong). b Apoptosis as quantified by TUNEL staining.
c Vessel density was quantified using CD31 inmmunohistochemistry staining. The number of CD31 + vessels was counted in five Â 10 fields. The value represents average7s.d. et al., 29 reported that the IL-12 upregulated Fas/FasL expression, induced cell apoptosis and the rejection of murine prostate carcinoma in mice. Several chemotherapeutic agents have also been shown to mediate cell death via the Fas/FasL pathway. [30] [31] [32] [33] In the present study, intratumor Ad.mIL-12 gene therapy upregulated the expression of both Fas and FasL in the treated and untreated tumors (Table 2 ). This upregulation was specific for IL-12 as intratumor injection of Ad.b-gal had no effect ( Figure 7 , Table 2 ). Therefore, the Fas pathway may be one mechanism involved in IL-12-induced tumor suppression in this model. In addition to stimulating cell surface Fas and FasL, intratumor Ad.mIL-12 gene therapy downregulated VEGF expression, decreased tumor vessel density and increased tumor cell apoptosis (Figure 7) .
The lack of therapeutic options for patients with relapsed Ewing's sarcoma argues for the development of innovative therapies. Taken together, our data suggest that IL-12 gene therapy may offer an effective approach for chemotherapy-resistant Ewing's sarcoma both at local and distant sites. Local gene delivery may also lessen the undesirable toxic complications seen with systemic IL-12 protein therapy.
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